Product Name :
Ralimetinib (LY2228820)
CAS No.:
862507-23-1
Purity :
> 99%
Shipping:
Shipped on dry ice.
Storage :
Powder: -20 °C, 3 years; 4 °C, 2 yearsIn solvent: -80 °C, 6 months; -20 °C, 1 month
SMILES:
CC(C)(C)C[N]1C(=NC2=C1N=C(C=C2)C3=C(N=C([NH]3)C(C)(C)C)C4=CC=C(F)C=C4)N.C[S](O)(=O)=O.C[S](O)(=O)=O
Product Description :
Ralimetinib (LY2228820) is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.
Formula:
C26H37FN6O6S2
Molecular Weight :
612.{{Asfotase alfa} web|{Asfotase alfa} Biological Activity|{Asfotase alfa} Description|{Asfotase alfa} supplier|{Asfotase alfa} Cancer} 74
Synonyms:
Additional Information:
|CAS No.{{Lacutamab} MedChemExpress|{Lacutamab} Protocol|{Lacutamab} In stock|{Lacutamab} supplier|{Lacutamab} Cancer} 862507-23-1 ; |Formula C26H37FN6O6S2 ; |Molecular Weight 612.PMID:35901518 74 ; |SMILES CC(C)(C)C[N]1C(=NC2=C1N=C(C=C2)C3=C(N=C([NH]3)C(C)(C)C)C4=CC=C(F)C=C4)N.C[S](O)(=O)=O.C[S](O)(=O)=O ; |Product Description Ralimetinib (LY2228820) is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2. ; |Purity > 99% ; |Shipping Shipped on dry ice. ; |Storage Powder: -20 °C, 3 years; 4 °C, 2 yearsIn solvent: -80 °C, 6 months; -20 °C, 1 month ; |Solubility Overview Soluble in DMSO